Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy

Shahrokh F. Shariat, Christian Bolenz, Guilherme Godoy, Yves Fradet, Raheela Ashfaq, Pierre I. Karakiewicz, Hendrik Isbarn, Claudio Jeldres, Jérôme Rigaud, Arthur I Sagalowsky, Yair Lotan

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose: pT1 urothelial carcinoma of the bladder is a potentially aggressive cancer diathesis with heterogeneous clinical behaviors. We tested whether the combination of immunohistochemical markers could risk stratify cases of pT1 urothelial carcinoma of the bladder at radical cystectomy. Materials and Methods: p53, p21, pRB, p27, survivin and Ki-67 immunohistochemical staining was performed on representative urothelial carcinoma of the bladder specimens of 80 patients with pT1 urothelial carcinoma of the bladder treated with radical cystectomy and bilateral pelvic lymphadenectomy (median followup 61.6 months). Results: p53 expression was altered in 25% of patients, p21 in 46%, pRB in 39%, p27 in 35%, survivin in 49% and Ki-67 in 34%. On multivariable analyses p53, p27 and Ki-67 were independently associated with urothelial carcinoma of the bladder recurrence (HR 3.66, p = 0.033; HR 3.76, p = 0.048 and HR 3.96, p = 0.021, respectively) and disease specific mortality (HR 5.25, p = 0.016; HR 3.68, p = 0.043 and HR 6.23, p = 0.009, respectively). The combination of these 3 biomarkers stratified cases into statistically significantly different risk groups for disease recurrence (p <0.001) and disease specific mortality (p <0.001). The addition of the number of altered markers increased the concordance indices of the base model that included grade, lymph node status, lymphovascular invasion and concomitant carcinoma in situ for disease recurrence and disease specific survival from 54.7% to 71.7% and from 64.3% to 77.5%, respectively. Conclusions: Assessment of p53, p27 and Ki-67 in urothelial carcinoma of the bladder specimens improves the prediction of recurrence-free and urothelial carcinoma of the bladder specific survival in patients with pT1 disease at radical cystectomy. These markers may help stratify the heterogeneous population of patients with pT1 disease into risk groups that can be used to guide clinical decision making regarding observation vs adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)78-84
Number of pages7
JournalJournal of Urology
Volume182
Issue number1
DOIs
StatePublished - Jul 2009

Fingerprint

Cystectomy
Urinary Bladder
Carcinoma
Recurrence
Survival
Mortality
Disease Susceptibility
Carcinoma in Situ
Lymph Node Excision
Biomarkers
Lymph Nodes
Observation
Staining and Labeling
Population
Neoplasms

Keywords

  • cystectomy
  • immunohistochemistry
  • recurrence
  • survival
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. / Shariat, Shahrokh F.; Bolenz, Christian; Godoy, Guilherme; Fradet, Yves; Ashfaq, Raheela; Karakiewicz, Pierre I.; Isbarn, Hendrik; Jeldres, Claudio; Rigaud, Jérôme; Sagalowsky, Arthur I; Lotan, Yair.

In: Journal of Urology, Vol. 182, No. 1, 07.2009, p. 78-84.

Research output: Contribution to journalArticle

Shariat, SF, Bolenz, C, Godoy, G, Fradet, Y, Ashfaq, R, Karakiewicz, PI, Isbarn, H, Jeldres, C, Rigaud, J, Sagalowsky, AI & Lotan, Y 2009, 'Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy', Journal of Urology, vol. 182, no. 1, pp. 78-84. https://doi.org/10.1016/j.juro.2009.02.125
Shariat, Shahrokh F. ; Bolenz, Christian ; Godoy, Guilherme ; Fradet, Yves ; Ashfaq, Raheela ; Karakiewicz, Pierre I. ; Isbarn, Hendrik ; Jeldres, Claudio ; Rigaud, Jérôme ; Sagalowsky, Arthur I ; Lotan, Yair. / Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. In: Journal of Urology. 2009 ; Vol. 182, No. 1. pp. 78-84.
@article{406662349f8c48fdb8055f1559ec9808,
title = "Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy",
abstract = "Purpose: pT1 urothelial carcinoma of the bladder is a potentially aggressive cancer diathesis with heterogeneous clinical behaviors. We tested whether the combination of immunohistochemical markers could risk stratify cases of pT1 urothelial carcinoma of the bladder at radical cystectomy. Materials and Methods: p53, p21, pRB, p27, survivin and Ki-67 immunohistochemical staining was performed on representative urothelial carcinoma of the bladder specimens of 80 patients with pT1 urothelial carcinoma of the bladder treated with radical cystectomy and bilateral pelvic lymphadenectomy (median followup 61.6 months). Results: p53 expression was altered in 25{\%} of patients, p21 in 46{\%}, pRB in 39{\%}, p27 in 35{\%}, survivin in 49{\%} and Ki-67 in 34{\%}. On multivariable analyses p53, p27 and Ki-67 were independently associated with urothelial carcinoma of the bladder recurrence (HR 3.66, p = 0.033; HR 3.76, p = 0.048 and HR 3.96, p = 0.021, respectively) and disease specific mortality (HR 5.25, p = 0.016; HR 3.68, p = 0.043 and HR 6.23, p = 0.009, respectively). The combination of these 3 biomarkers stratified cases into statistically significantly different risk groups for disease recurrence (p <0.001) and disease specific mortality (p <0.001). The addition of the number of altered markers increased the concordance indices of the base model that included grade, lymph node status, lymphovascular invasion and concomitant carcinoma in situ for disease recurrence and disease specific survival from 54.7{\%} to 71.7{\%} and from 64.3{\%} to 77.5{\%}, respectively. Conclusions: Assessment of p53, p27 and Ki-67 in urothelial carcinoma of the bladder specimens improves the prediction of recurrence-free and urothelial carcinoma of the bladder specific survival in patients with pT1 disease at radical cystectomy. These markers may help stratify the heterogeneous population of patients with pT1 disease into risk groups that can be used to guide clinical decision making regarding observation vs adjuvant therapy.",
keywords = "cystectomy, immunohistochemistry, recurrence, survival, urinary bladder neoplasms",
author = "Shariat, {Shahrokh F.} and Christian Bolenz and Guilherme Godoy and Yves Fradet and Raheela Ashfaq and Karakiewicz, {Pierre I.} and Hendrik Isbarn and Claudio Jeldres and J{\'e}r{\^o}me Rigaud and Sagalowsky, {Arthur I} and Yair Lotan",
year = "2009",
month = "7",
doi = "10.1016/j.juro.2009.02.125",
language = "English (US)",
volume = "182",
pages = "78--84",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy

AU - Shariat, Shahrokh F.

AU - Bolenz, Christian

AU - Godoy, Guilherme

AU - Fradet, Yves

AU - Ashfaq, Raheela

AU - Karakiewicz, Pierre I.

AU - Isbarn, Hendrik

AU - Jeldres, Claudio

AU - Rigaud, Jérôme

AU - Sagalowsky, Arthur I

AU - Lotan, Yair

PY - 2009/7

Y1 - 2009/7

N2 - Purpose: pT1 urothelial carcinoma of the bladder is a potentially aggressive cancer diathesis with heterogeneous clinical behaviors. We tested whether the combination of immunohistochemical markers could risk stratify cases of pT1 urothelial carcinoma of the bladder at radical cystectomy. Materials and Methods: p53, p21, pRB, p27, survivin and Ki-67 immunohistochemical staining was performed on representative urothelial carcinoma of the bladder specimens of 80 patients with pT1 urothelial carcinoma of the bladder treated with radical cystectomy and bilateral pelvic lymphadenectomy (median followup 61.6 months). Results: p53 expression was altered in 25% of patients, p21 in 46%, pRB in 39%, p27 in 35%, survivin in 49% and Ki-67 in 34%. On multivariable analyses p53, p27 and Ki-67 were independently associated with urothelial carcinoma of the bladder recurrence (HR 3.66, p = 0.033; HR 3.76, p = 0.048 and HR 3.96, p = 0.021, respectively) and disease specific mortality (HR 5.25, p = 0.016; HR 3.68, p = 0.043 and HR 6.23, p = 0.009, respectively). The combination of these 3 biomarkers stratified cases into statistically significantly different risk groups for disease recurrence (p <0.001) and disease specific mortality (p <0.001). The addition of the number of altered markers increased the concordance indices of the base model that included grade, lymph node status, lymphovascular invasion and concomitant carcinoma in situ for disease recurrence and disease specific survival from 54.7% to 71.7% and from 64.3% to 77.5%, respectively. Conclusions: Assessment of p53, p27 and Ki-67 in urothelial carcinoma of the bladder specimens improves the prediction of recurrence-free and urothelial carcinoma of the bladder specific survival in patients with pT1 disease at radical cystectomy. These markers may help stratify the heterogeneous population of patients with pT1 disease into risk groups that can be used to guide clinical decision making regarding observation vs adjuvant therapy.

AB - Purpose: pT1 urothelial carcinoma of the bladder is a potentially aggressive cancer diathesis with heterogeneous clinical behaviors. We tested whether the combination of immunohistochemical markers could risk stratify cases of pT1 urothelial carcinoma of the bladder at radical cystectomy. Materials and Methods: p53, p21, pRB, p27, survivin and Ki-67 immunohistochemical staining was performed on representative urothelial carcinoma of the bladder specimens of 80 patients with pT1 urothelial carcinoma of the bladder treated with radical cystectomy and bilateral pelvic lymphadenectomy (median followup 61.6 months). Results: p53 expression was altered in 25% of patients, p21 in 46%, pRB in 39%, p27 in 35%, survivin in 49% and Ki-67 in 34%. On multivariable analyses p53, p27 and Ki-67 were independently associated with urothelial carcinoma of the bladder recurrence (HR 3.66, p = 0.033; HR 3.76, p = 0.048 and HR 3.96, p = 0.021, respectively) and disease specific mortality (HR 5.25, p = 0.016; HR 3.68, p = 0.043 and HR 6.23, p = 0.009, respectively). The combination of these 3 biomarkers stratified cases into statistically significantly different risk groups for disease recurrence (p <0.001) and disease specific mortality (p <0.001). The addition of the number of altered markers increased the concordance indices of the base model that included grade, lymph node status, lymphovascular invasion and concomitant carcinoma in situ for disease recurrence and disease specific survival from 54.7% to 71.7% and from 64.3% to 77.5%, respectively. Conclusions: Assessment of p53, p27 and Ki-67 in urothelial carcinoma of the bladder specimens improves the prediction of recurrence-free and urothelial carcinoma of the bladder specific survival in patients with pT1 disease at radical cystectomy. These markers may help stratify the heterogeneous population of patients with pT1 disease into risk groups that can be used to guide clinical decision making regarding observation vs adjuvant therapy.

KW - cystectomy

KW - immunohistochemistry

KW - recurrence

KW - survival

KW - urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=67349241506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349241506&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2009.02.125

DO - 10.1016/j.juro.2009.02.125

M3 - Article

C2 - 19447418

AN - SCOPUS:67349241506

VL - 182

SP - 78

EP - 84

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -